The MiR-383-LDHA Axis Regulates Cell Proliferation, Invasion and Glycolysis in Hepatocellular Cancer

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2017 Mar 16

PMID 28293396

Citations 20

Authors

Zhixiong Fang

Langqiu He

Hui Jia

Qiusheng Huang

Dan Chen

Zhiwei Zhang

Affiliations

Soon will be listed here.

Abstract

Objectives: To explore the correlation between expression patterns and functions of miR-383 and LDHA in hepatocellular cancer (HCC).

Materials And Methods: We detected the expression of miR-383 and LDHA in 30 HCC tissues and their matched adjacent normal tissues using qRT-PCR. Then we performed MTT assay, foci formation assay, transwell migration assay, glucose uptake assay and lactate production assay to explore the function of miR-383 in cell proliferation, invasion and glycolysis in HCC cell lines. Luciferase reporter assay was used to explore whether LDHA was a target gene of miR-383. Western blot and qRT-PCR were used to further confirm LDHA was targeted by miR-383. Then the above functional experiments were repeated to see whether the function of LDHA could be inhibited by miR-383.

Results: The results of qRT-PCR showed that miR-383 was down-regulated in HCC tissues compared with their matched adjacent normal tissues. Functional experiments showed that overexpression of miR-383 significantly suppressed cell proliferation, invasion and glycolysis. Luciferase reporter assay showed LDHA was a target gene of miR-383 and expression of LDHA was inversely correlated with that of miR-383 in HCC. Besides, increased cell proliferation, invasion and glycolysis triggered by LDHA could be inhibited by overexpression of miR-383 in HCC cell lines.

Conclusion: Our study proved that miR-383 is down-regulated in HCC and acts as a tumor suppressor through targeting LDHA. Targeting the miR-383-LDHA axis might be a promising strategy in HCC treatment.

Citing Articles

MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.

Wang H, Bai C, Dang X, Wang H Mol Biol Rep. 2024; 51(1):170.

PMID: 38252234 DOI: 10.1007/s11033-023-08964-7.

Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.

Feng Q, Huang Z, Song L, Wang L, Lu H, Wu L Eur J Med Res. 2023; 28(1):306.

PMID: 37649103 PMC: 10466881. DOI: 10.1186/s40001-023-01300-6.

Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma.

Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S Front Oncol. 2023; 12:1063423.

PMID: 36686771 PMC: 9853001. DOI: 10.3389/fonc.2022.1063423.

MicroRNA-383: A tumor suppressor miRNA in human cancer.

Jafarzadeh A, Noori M, Sarrafzadeh S, Tamehri Zadeh S, Nemati M, Chatrabnous N Front Cell Dev Biol. 2022; 10:955486.

PMID: 36313570 PMC: 9608775. DOI: 10.3389/fcell.2022.955486.

MicroRNAs as Regulators of Cancer Cell Energy Metabolism.

Muthukumaran N, Velusamy P, Akino Mercy C, Langford D, Natarajaseenivasan K, Shanmughapriya S J Pers Med. 2022; 12(8).

PMID: 36013278 PMC: 9410355. DOI: 10.3390/jpm12081329.

References

Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

Li K, Pang J, Lau K, Zhou L, Mao Y, Wang Y . MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2012; 23(4):413-25. PMC: 8029115. DOI: 10.1111/bpa.12014. View

Xu Z, Zeng X, Tian D, Xu H, Cai Q, Wang J . MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1. Biochem Biophys Res Commun. 2014; 453(4):833-8. DOI: 10.1016/j.bbrc.2014.10.047. View

Yao F, Zhao T, Zhong C, Zhu J, Zhao H . LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 2012; 34(1):25-31. DOI: 10.1007/s13277-012-0506-0. View

Xu D, Ma P, Gao G, Gui Y, Niu X, Jin B . MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. Tumour Biol. 2015; 36(10):7743-53. DOI: 10.1007/s13277-015-3378-2. View

He Z, Cen D, Luo X, Li D, Li P, Liang L . Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol. 2013; 30(2):557. DOI: 10.1007/s12032-013-0557-0. View

Lian J, Tian H, Liu L, Zhang X, Li W, Deng Y . Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 2011; 1:e94. PMC: 3032325. DOI: 10.1038/cddis.2010.70. View

Wang X, Ren Y, Wang Z, Xiong X, Han S, Pan W . Down-regulation of 5S rRNA by miR-150 and miR-383 enhances c-Myc-rpL11 interaction and inhibits proliferation of esophageal squamous carcinoma cells. FEBS Lett. 2015; 589(24 Pt B):3989-97. DOI: 10.1016/j.febslet.2015.11.012. View

Rasool M, Rashid S, Arooj M, Ansari S, Khan K, Malik A . New possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014; 34(4):1563-71. View

10.

Huang H, Tian H, Duan Z, Cao Y, Zhang X, Sun F . microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. Cell Signal. 2014; 26(5):903-11. DOI: 10.1016/j.cellsig.2014.01.016. View

11.

Tabrizian P, Roayaie S, Schwartz M . Current management of hepatocellular carcinoma. World J Gastroenterol. 2014; 20(30):10223-37. PMC: 4130831. DOI: 10.3748/wjg.v20.i30.10223. View

12.

Raza A, Sood G . Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014; 20(15):4115-27. PMC: 3989948. DOI: 10.3748/wjg.v20.i15.4115. View

13.

Cai Z, Zhao J, Li J, Peng D, Wang X, Chen T . A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 2010; 9(12):2617-28. PMC: 3101851. DOI: 10.1074/mcp.M110.000661. View

14.

Farazi T, Hoell J, Morozov P, Tuschl T . MicroRNAs in human cancer. Adv Exp Med Biol. 2013; 774:1-20. PMC: 3704221. DOI: 10.1007/978-94-007-5590-1_1. View

15.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

16.

Hung C, Chiu Y, Chen C, Hu T . MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014; 2014:486407. PMC: 3996893. DOI: 10.1155/2014/486407. View

17.

DAnzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M . The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules. 2014; 19(5):6393-406. PMC: 6271763. DOI: 10.3390/molecules19056393. View

18.

Wang J, Wang H, Liu A, Fang C, Hao J, Wang Z . Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget. 2015; 6(23):19456-68. PMC: 4637298. DOI: 10.18632/oncotarget.3318. View

19.

Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D . Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013; 34(3):1523-30. DOI: 10.1007/s13277-013-0679-1. View

20.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View